Health insurance is covering fewer medications, with Medicare patients facing stricter restrictions. Profit-driven ...

On average, the study showed that Medicare prescription drug plans now cover just 56% of analyzed medications – a steep drop ...

Q1 2025 Earnings Call Transcript May 9, 2025 Ocugen, Inc. beats earnings expectations. Reported EPS is $-0.05, expectations ...

Gilead Sciences, Inc. today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated ...

Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024 ...

Cumberland Pharmaceuticals, Inc. ( NASDAQ: CPIX) Q1 2025 Earnings Conference Call May 6, 2024 4:30 PM ET Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

Amtagvi has the potential to be approved in three new markets in 2025, including the United Kingdom, Canada, and all EU member states. Recently, the i CTC and Iovance's contract manufacturer ...

On January 13, 2025, IAC announced that its Board of Directors had approved a plan to spin off its entire stake in ANGI. On ...

Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and recent business ...

Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First QuarterInspire Reports Year-over-Year Rev ...

Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask ...